TY  - JOUR
AU  - Martin, Ernesto
AU  - Castillo, Juan C
AU  - Gonzalez-Manzanares, Rafael
AU  - Lopez Aguilera, Jose
AU  - Perea, Jorge
AU  - Anguita, Manuel
PY  - 2021
DO  - 10.5603/CJ.a2021.0169
UR  - http://hdl.handle.net/10668/21660
T2  - Cardiology journal
AB  - Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently been introduced as an oral antidiabetic therapy; proving to be safe and showing a reduction in the risk of cardiovascular events in patients with type 2 diabetes (T2D) [1–3], especially...
LA  - en
PB  - Wydawnictwo Via Medica
KW  - Canagliflozin
KW  - Diabetes mellitus, type 2
KW  - Heart failure
KW  - Humans
KW  - Natriuretic peptide, brain
KW  - Natriuretic peptides
KW  - Sodium-glucose transporter 2 inhibitors
TI  - Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?
TY  - Research article
VL  - 29
ER  -